Dermatológia pre prax 4/2022

Psoriatic arthritis

Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. Personalised approach to treating early diagnosed and treated PsA may be optimal. The identification of predictor of treatment response in PsA trough biomarkers is one maine research areas of the Group for Research and Assesment of Psoriasis and Psoriatic Arthritis. Dermatologists play an important role in screening of PsA due to the fact that psoriasis precedes arthritis in most cases. Subclinical musculoskeletal changes among patients with psoriasis are a sign of risk for the development of PsA. Screning questionnaires for use in the dermatology praxis to identify PsA in patients with psoriasis may be helpful in identifying early PsA.

Keywords: psoriatic arthritis, biomarkers, early diagnostics, treatment, prognosis